All News

2019

May

Media Release / May 23, 2019

Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event

Read More
Media Release / May 22, 2019

Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment

Read More
A doctor discusses different clinical trial options with a patient.
Story / May 17, 2019

Respiratory clinical trials: Putting patients at the heart of research

All treatments that exist today started with patients volunteering to participate in a study and healthcare professionals offering their expertise.

Read More
Media Release / May 16, 2019

Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders

Read More
Featured News / May 15, 2019

SOLAR-1 NEJM Publication

Read More
Media Release / May 10, 2019

Novartis data at AAN show Gilenya® is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS

Read More
Vice President and Head of US Hematology at Novartis shares her story for “Novartis Presents: Women in Science.”
Story / May 09, 2019

Women in Science: Sandrine Piret-Gérard

Sandrine Piret-Gérard, Vice President and Head of US Hematology at Novartis, reflects on what’s inspired her career in health care.

Read More
Media Release / May 09, 2019

Sandoz demonstrates strategic focus on China, with first-of-a-kind generic approval under Quality Consistency Evaluation system

Read More
Media Release / May 09, 2019

Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care

Read More
Media Release / May 08, 2019

Novartis data at AAN show Mayzent's® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS

Read More

Pages

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More